NEW YORK (GenomeWeb News) — LabCorp today said it has licensed DNA-methylation technology from Veridex that may help it develop and market an assay to detect prostate cancer.
The reference lab giant said its assay will quantify in human samples the level of the gene GST-Pi, which has been linked to prostate cancer.
If the technology is used in conjunction with histopathology testing it may “provide a more sensitive and accurate detection of prostate cancer than histology alone,” LabCorp said.
The company said it will offer the assay for use on biopsies presenting “suspicious histopathology,” and for patients showing repeatedly elevated prostate specific antigen values but who have repeatedly negative biopsies.
LabCorp said it is the first full-service, national laboratory to license this IP in the US.
Financial terms of the agreement were not released.